Page 5 - Patanjali Ayurved

Ruchi Soya soared 90 times in 5 months; should you buy?

From Rs 16.9 to Rs 1,519 in five months, the stock has seen a spectacular rise of 8,988 per cent

Covid updates: Nearly 20k cases in 24 hrs in India, World tally tops 10 mn

In his monthly address 'Mann Ki Baat' today, Prime Minister Narendra Modi asked people to be more careful during the 'unlock' period

Notice sent to NIMS Jaipur for unauthorised trials of Patanjali's Coronil

The Rajasthan government has clarified that the drug cannot be used as a medicine in the state without the permission of the Ministry of AYUSH

Coronavirus updates: Over 17,000 new cases, record recoveries in India

India death toll crosses 15,000; Maharashtra, Delhi, Tamil Nadu account for 68% of cases added today

Will take action against sale of Patanjali Covid-19 drug in Rajasthan: Govt

Neither has anyone applied to the state government nor has the state government given any permission in this regard, State Health Minister Raghu Sharma said

Patanjali Ayurved submits report on its Covid-19 drug to Ayush ministry

"Baba Ramdev has produced a new medicine. Whatever research they have done, it should come to the Ayush Ministry for authentication," Naik said

India-US 'green' corridor for air travel, and other coronavirus updates

The total number of Covid-19 cases in Delhi crossed the 66,000 mark, with the biggest single-day spike of 3,947 fresh infections being reported on Tuesday

Good that Ramdev has given Covid-19 medicine, but rules matter: Minister

The Ministry had also issued a notification in April stating the requirements and the manner in which the research studies on Covid-19 with AYUSH interventions/medicines should be undertaken

Govt asks Ramdev's Patanjali group to stop Covid-19 drug ads, seeks details

Hours after the launch, the ministry denied knowledge of the drugs and asked the group to refrain from publicising them.

Patanjali announces Covid-19 medicine; govt frowns and asks for details

Patanjali has also been asked for details of the sample size, sites and hospitals where the research study was conducted

India tally rises to 440K; Patanjali launches ayurvedic drug for Covid-19

According to government data, the situation in India is not as alarming as some of the other countries, given a limited spread on a per-capita basis

Patanjali's Rs 250 crore NCD subscribed within three minutes of opening

The fund-raising will be used to meet the Haridwar-based company's working capital requirements and strengthen the supply chain network

Top 10 biz headlines: Boeing cuts 12,000 jobs, SBI slashes FD rate and more

Here are the top 10 headlines on Thursday morning

Patanjali to issue debentures worth Rs 250 cr; bidding to start on May 28

NCDs will carry a coupon rate of 10.10 per cent with a tenure of three years

Ramdev's tips to ward off coronavirus anger health professionals

In a promotional video made public this week, Ramdev says 'we've done scientific research and found Ashwagandha doesn't allow blending of corona protein with human protein'

Patanjali gets one more week to complete Rs 4,350-cr Ruchi Soya deal

A three-member NCLAT bench headed by Chairperson Justice S J Mukhopadhaya extended the deadline to December 23

SBI, other PSBs to lend Rs 4,000 cr to Patanjali for Ruchi Soya acquisition

The loan to Patanjali Ayurved comes a few weeks after CARE Ratings withdrew its rating on the firm in October

Patanjali secures Rs 3,200 cr loan from SBI, other banks to buy Ruchi Soya

Patanjali said it has got loans of Rs 1,200 crore from SBI, Rs 700 crore from PNB, Rs 600 crore from UBI, Rs 400 crore from Syndicate Bank and Rs 300 crore from Allahabad Bank

NCLAT extends deadline to implement Patanjali's Ruchi Soya bid to Dec 16

The appellate is hearing some other matters related to Ruchi Soya, which are slated to be heard on December 9

Patanjali stabilises biz after a year of faltering sales; revenue up 2.4%

The top line growth for Patanjali that once used to grow by leaps and bounds - between 2012-13 and 2016-17 - has come down since